CO2023014770A2 - Degradadores de cdk2 y sus usos - Google Patents

Degradadores de cdk2 y sus usos

Info

Publication number
CO2023014770A2
CO2023014770A2 CONC2023/0014770A CO2023014770A CO2023014770A2 CO 2023014770 A2 CO2023014770 A2 CO 2023014770A2 CO 2023014770 A CO2023014770 A CO 2023014770A CO 2023014770 A2 CO2023014770 A2 CO 2023014770A2
Authority
CO
Colombia
Prior art keywords
degraders
cdk2
compositions
methods
present
Prior art date
Application number
CONC2023/0014770A
Other languages
English (en)
Inventor
Xiaozhang Zheng
Yi Zhang
Xiao Zhu
Robert Aversa
Philip Collier
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of CO2023014770A2 publication Critical patent/CO2023014770A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención proporciona compuestos, composiciones de ellos, y métodos de uso de los mismos.
CONC2023/0014770A 2021-05-07 2023-10-31 Degradadores de cdk2 y sus usos CO2023014770A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163185929P 2021-05-07 2021-05-07
PCT/US2022/028076 WO2022236058A1 (en) 2021-05-07 2022-05-06 Cdk2 degraders and uses thereof

Publications (1)

Publication Number Publication Date
CO2023014770A2 true CO2023014770A2 (es) 2023-11-10

Family

ID=83932976

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0014770A CO2023014770A2 (es) 2021-05-07 2023-10-31 Degradadores de cdk2 y sus usos

Country Status (12)

Country Link
US (1) US20230110180A1 (es)
EP (1) EP4334307A1 (es)
KR (1) KR20240020735A (es)
CN (1) CN117715904A (es)
AR (1) AR125798A1 (es)
AU (1) AU2022271290A1 (es)
BR (1) BR112023023223A2 (es)
CA (1) CA3217792A1 (es)
CO (1) CO2023014770A2 (es)
IL (1) IL308314A (es)
TW (1) TW202309030A (es)
WO (1) WO2022236058A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220640A1 (en) * 2022-05-10 2023-11-16 Biotheryx, Inc. Cdk protein degraders, pharmaceutical compositions, and therapeutic applications
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323469A (en) * 1980-10-28 1982-04-06 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Process for O-acylating phenol derivatives and acylating compositions for this purpose
CN1826120A (zh) * 2003-07-23 2006-08-30 幸讬制药公司 用于发炎与免疫相关用途的化合物
KR20210121186A (ko) * 2019-01-31 2021-10-07 화이자 인코포레이티드 Cdk2에 대한 억제 활성을 갖는 3-카본일아미노-5-사이클로펜틸-1h-피라졸 화합물

Also Published As

Publication number Publication date
US20230110180A1 (en) 2023-04-13
AU2022271290A1 (en) 2023-11-23
TW202309030A (zh) 2023-03-01
CN117715904A (zh) 2024-03-15
WO2022236058A1 (en) 2022-11-10
IL308314A (en) 2024-01-01
AR125798A1 (es) 2023-08-16
CA3217792A1 (en) 2022-11-10
BR112023023223A2 (pt) 2024-01-30
EP4334307A1 (en) 2024-03-13
KR20240020735A (ko) 2024-02-15

Similar Documents

Publication Publication Date Title
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
CO2021007068A2 (es) Degradadores de irak y usos de los mismos
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
CO2022008406A2 (es) Degradadores de irak y usos de los mismos
CL2019000628A1 (es) Anticuerpos anti-pd-1 y sus usos.
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
CO2023008362A2 (es) Degradadores de irak y sus usos
CO2020010303A2 (es) Conjugados de il-15, y sus usos
CO2023014770A2 (es) Degradadores de cdk2 y sus usos
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
ECSP099785A (es) Anticuerpos anti-notch1 nrr y sus métodos de uso
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
UY38403A (es) Moduladores de la alfa-1 antitripsina
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
CO2018008304A2 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
CO2023006818A2 (es) Degradadores de irak y sus usos
CO2023014622A2 (es) Conjugados de anticuerpo-fármaco anti-c-met
CL2022001546A1 (es) Formulaciones líquidas de tasimelteón y métodos para su uso